Sphera Funds Management LTD. bought a new position in shares of AC Immune SA (NASDAQ:ACIU) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 503,563 shares of the company’s stock, valued at approximately $4,029,000. Sphera Funds Management LTD. owned approximately 0.76% of AC Immune at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. GSA Capital Partners LLP bought a new position in AC Immune during the third quarter worth about $110,000. JPMorgan Chase & Co. bought a new position in AC Immune during the third quarter worth about $142,000. Compagnie Lombard Odier SCmA lifted its holdings in AC Immune by 858.3% during the third quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock worth $268,000 after acquiring an additional 30,039 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in AC Immune by 131.6% during the third quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock worth $418,000 after acquiring an additional 29,720 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new position in AC Immune during the third quarter worth about $626,000. Hedge funds and other institutional investors own 29.06% of the company’s stock.
ACIU opened at $11.15 on Friday. The stock has a market capitalization of $702.10 million, a price-to-earnings ratio of -37.17 and a beta of 1.27. AC Immune SA has a 1 year low of $7.16 and a 1 year high of $17.40.
AC Immune (NASDAQ:ACIU) last released its earnings results on Tuesday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. The business had revenue of $2.34 million for the quarter, compared to the consensus estimate of $1.71 million. AC Immune had a negative return on equity of 24.14% and a negative net margin of 146.09%. Equities research analysts forecast that AC Immune SA will post -0.85 earnings per share for the current fiscal year.
Several research analysts have weighed in on ACIU shares. BidaskClub lowered AC Immune from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. ValuEngine downgraded AC Immune from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Zacks Investment Research downgraded AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. Finally, Leerink Swann assumed coverage on AC Immune in a research note on Monday, November 12th. They issued an “outperform” rating and a $18.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $15.25.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: Why is insider trading harmful?
Want to see what other hedge funds are holding ACIU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AC Immune SA (NASDAQ:ACIU).
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.